The cellular transcription factor Brn-3a differentially regulates different human papilloma virus (HPV)-16 variants that are associated with different risks of progression to cervical carcinoma in infected humans. The upstream regulatory regions (URRs) of high-and intermediate-risk HPV-16 variants are activated by the cellular transcription factor Brn-3a, whereas the URR of a low-risk HPV-16 variant is not. In this study, we show in transfection assays that Brn-3a and the smoking-related substance nicotine produce stronger responsiveness of the URR of the low-and high-risk variants than with either factor alone, but not the intermediate-risk variant. We determined that this synergistic activity of Brn-3a/ nicotine is due to two nucleotide differences in the URR, crucial for oncogenic E6/E7 transactivation. Mutant constructs in which the nucleotide residues were substituted alter Brn-3a/nicotine responsiveness. Importantly, women smokers with high levels of Brn-3a infected with low-or high-risk HPV-16 variants have augmented E6 levels, and were more frequently diagnosed with higher grades of cervical intraepithelial neoplasia (CIN) and cancer, as compared with non-smokers who were infected with similar variants and expressed similar levels of Brn3a. Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not.
Introduction
Cervical cancer is the second most common cancer in women worldwide and more than 0.5 million new cases are reported each year (Bosch et al., 1995; zur Hausen, 2009) . A key role in this disease is had by the high-risk human papilloma viruses, namely HPV-16 and HPV-18, which are present in a high proportion of women with cervical dysplasia and encode specific transforming early-open-reading-frame E6/E7 proteins (Cox et al., 1986; Cripe et al., 1987; Burghardt et al., 1991; Morris et al., 1993; Miller, 2001; zur Hausen, 2009) . Several studies have shown that HPV depends on these E6/E7 oncoproteins for cervical cell transformation (Cripe et al., 1987; Morris et al., 1993) .
In addition, it is now generally accepted that smoking is a common environmental causative agent associated with cervical cancer (Hellberg et al., 1988; McCann et al., 1992; Prokopczyk et al., 1997; Tsai et al., 2007) , and interestingly, some studies have now shown a powerful synergy between HPV-16 and cervical cancer in situ for smokers (Anthony et al., 2006) . Despite this, little is known about the mechanism by which smoking and its related substances influence cervical carcinogenesis.
Some specific studies focus on the immunosuppression induced by smoking-related substances (Anthony et al., 2006) or on smoking-induced cellular proliferation of keratinocytes (Lane et al., 2005) . In contrast, no studies have analysed the direct or indirect role had by these substances in transactivation of the HPV viral genome, nor do they explain why some women smokers are more susceptible to accelerated disease progression upon HPV infection.
Interestingly, cellular transcription factors bind specific motifs of the HPV upstream regulatory region (URR) to regulate the production of the oncogenic E6/ E7 product. In particular, Brn-3a is member of the POU family of cellular transcription factors, which binds to a specific motif of the HPV URR and strongly stimulates its activity (Lillycrop et al., 1992; Morris et al., 1994) . We have shown in previous studies that Brn-3a is overexpressed in human cervical carcinoma biopsies (Ndisang et al., 2000; Sindos et al., 2003a, b) , and that the inhibition of its expression in human cervical cancer cells abrogates HPV gene expression and reduces cellular growth and anchorage independence in vitro, as well as the ability to form tumours in vivo (Ndisang et al., 1999 (Ndisang et al., , 2001 ).
In addition, our previous studies have shown that the cellular transcription factor Brn-3a, differentially regulates different HPV-16 variants that have previously been shown to be associated with different risks of progression to cervical carcinoma (Bible et al., 2000; Ndisang et al., 2006b) . In those studies, we showed that the URRs of the HPV high-risk V2 variant and the intermediate-risk V1 variant were activated by Brn-3a, whereas the URR of the low-risk V5 variant was not (Bible et al., 2000; Ndisang et al., 2006b) .
In this study, we therefore examined the effect of Brn3a and smoking on different HPV URR variants using both human cervical material and transfection of cultured cervical cells. We report in this study for the first time, that the cellular factor Brn-3a and the smoking-related substance nicotine interact to differentially transactivate the HPV URR in a variant-specific manner.
Results
To determine the levels of the mRNA encoding the ongogenic E6 product and the cellular transcription factor Brn-3a in the cervix of both smokers and nonsmokers, we used our previously defined reversetranscriptase PCR procedure (Sindos et al., 2003a; Ndisang et al., 2006a, b) . We observed that the mean E6 mRNA for smokers was higher than that of nonsmokers (Table 1) . In contrast, the mean Brn-3a mRNA for smokers was approximately the same as that of nonsmokers (Table 1) . This suggested a potential interaction of Brn-3a and smoking in regulating the HPV URR. However, the situation is complicated by the existence of different variants of HPV, which respond differently to Brn-3a, and hence produce different risks of disease (Ndisang et al., 2006b) .
To identify the specific HPV-16 variant that the patients who smoked or did not smoke were infected with, we used a RFLP (Restriction Fragment Length Polymorphism) assay, which was adapted from the study by Bible et al. (2000) , and have used previously to type the DNA of different HPV variants in clinical samples (Sindos et al., 2003a; Ndisang et al., 2006a) . Thus, we were able to identify the type of HPV-16 variant each of the women were infected with (Table 1) . Importantly, the RFLP-based typing data, indicate that, even though the cervical material used for this assay were obtained from women who attended clinics in England and Brazil, there were five predominant and common variants among them, that is, variant 1, variant 2, variant 5, variant 7 and variant 8 (Bible et al., 2000; Ndisang et al., 2006b) . Of these, the most important variants were as follows: variant 5 that was previously shown to be negatively associated with viral transcription and cervical neoplasia (odds ratio 0.2); variant 2 that is positively associated with disease (odds ratio 2.57); and variant 1 that shows an intermediate risk of disease (Bible et al., 2000; Ndisang et al., 2006b) . Hence, it was now possible to characterize each patient as a smoker, non-smoker or ex-smoker, in terms of the HPV variant they were infected with and in terms of E6 and Brn-3a mRNA levels. In this manner, the specific effect of Brn-3a on the different URR variants became apparent as shown in Table 2 and in Figures 1  and 2 . For example, for those women who were infected with V5 and express Brn-3a in their cervix, the E6 mRNA was specifically detected only in the cervix of smokers, but not non-smokers, even though they were infected with V5 and also present similar levels of Brn-3a in their cervix (Table 2 , Figures 1 and 2) . Moreover, for those women who were infected with V2 and have Brn-3a in their cervix, the mean E6 for smokers is significantly higher statistically than that of the corresponding V2 non-smokers (P ¼ 0.0009) ( Table 2 ). In contrast, for those women who were The mean Brn-3a and E6 mRNA values for those women who are infected only a with either HPV variant 1 (V1), variant 2 (V2) or variant 5 (V5) must be noted. It must also be noted that there is a significant difference between the mean E6 mRNA for the women smokers and non-smokers who are infected only with either V1, V2 or V5 as shown in the right panel, designated by *, as compared with the mean E6 mRNA of the total women smokers and non-smokers in the left panel, where there is no significant difference as designated by **. In both panels, it must be noted that there is no significant difference between the mean Brn-3a in the smokers and non-smokers categories. The notation/r 2 /4 0, signifies that the expression of E6 mRNA parallels that of Brn-3a. * Brn-3a and nicotine synergistically activate HPV variants D Ndisang et al infected with V1 and express Brn-3a in their cervix, the mean E6 for the V1 smokers was lower than that of the corresponding V1-infected women non-smokers (P ¼ 0.08) ( Table 2) . Interestingly, the relative increased level of E6 for V2-and V5-infected women smokers reflects the severity of cervical intraepithelial neoplasia (CIN) among these women (Table 3) , and the relative risk associated with disease progression compared with non-smokers (Table 4) . Thus, using logistic analysis, the odds ratio for Brn-3a-expressing women infected with V2 getting cervical cancer is 3.34 times greater as a smoker than as a non-smoker (Table 4 ). In addition, the odds ratio associated with CIN progression for women infected with V5, increased from 0.2, as reported by Bible et al. (2000) , to 3.2 as observed in this study for those who smoke and present Brn-3a (Table 4 ). This indicates that women who express Brn-3a in their cervix and are exposed to smoking are 16 times more susceptible to a progressive CIN upon V5 infection (Table 4) .
Although the population size of V5-infected women was small, the results were statistically significant (Table 2 ). These findings indicate that in the presence of smoking-related substances, this low-risk variant V5 induces cellular transformation in the cervix similar to high-risk variants (Tables 3 and 4) . Taking the results presented in this study together, it is clear that unlike the intermediate-risk V1 URR, the low-risk V5 and the high-risk V2 URRs appear to be upregulated in the presence of both Brn-3a and smoking-associated substances. This is of particular importance as our previous studies (Ndisang et al., 2006b ) indicated that Brn-3a alone has no effect on HPV expression in the V5 variant. 
Figure 2
The mRNA levels of Brn3a and E6 with the corresponding variant isolates in the cervix of some women smokers or women non-smokers in Recife, Brazil. The diagnostic restriction sites in the E5 sequence used to define V1, V2 and V5 were SspI and XcmI (Bible et al., 2000; Ndisang et al., 2006b) . Bullet points denote smokers. Table 3 The distribution of the different grades of cervical intraepithelial neoplasia (CIN) among Brn-3a-expressing women infected with either HPV-16 variant 1, variant 2 or variant 5 who are smokers, non-smokers or ex-smokers
Brn-3a women smokers or non-smokers infected with V1, V2 or V5
All subjects (n ¼ 158)
Smokers 25 (15.8 %) 3 (7.5 %) 15 (28.9 %) 6 (9.8 %) 1(20%) Non-smokers 36 (22.8 %) 5 (12.5%) 18 (34.6 %) 13 (21.3 %) 0 Ex-smokers 4 (2.5 %) 3 (7.5%) 1 (1.9%) 0 0
V2
Smokers 29 (18.4 %) 0 4 (7.7 %) 22 (36.1 %) 3 (60 %) Non-smokers 30 (19 %) 3 (7.5 %) 9 (17.3 %) 17 (27.9 %) 1 (20 %) Ex-smokers 3 (1.9 %) 2 (5 %) 1 (1.9 %) 0 0 V5 Smokers 15 (9.4 %) 9 (22.5 %) 3 (5.8 %) 3 (4.9 %) 0 Non-smokers 14 (8.9 %) 13 (32.5 %) 1 (1.9 %) 0 0 Ex-smokers 2 (1.3 %) 2 (5 %) 0 0 0 Abbreviation: HPV, human papilloma virus.
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To confirm patient results that smokers with Brn-3a who were infected with either V2 or V5 have augmented E6 levels, as compared with Brn-3a non-smokers infected with similar variants, we used our established co-transfection assay to analyse the effect of Brn-3a and smoking-related substances (Lee et al., 2005) . We cotransfected Brn-3a promoter constructs and luciferace reporter constructs containing the HPV URR variants 1, 2 and 5 (Ndisang et al., 2006b) , into the SiHa cervical carcinoma cell line and supplemented the medium with smoking-related subtances of cotinine or with nicotine.
In these experiments, we determined for the first time that the low-risk V5 and the high-risk V2 URRs, were more active in the presence of a combination of Brn-3a and nicotine than with either factor alone ( Figure 3 , middle and top right panels). In contrast, this was not the case with the intermediate-risk V1 URR, which was less active with Brn-3a and nicotine than with Brn-3a alone (Figure 3, top left panel) .
On the basis of the known differences in sequence between these URRs, we deduced that this Brn-3a and nicotine upregulating activity, occurs in the URRs of V2 and V5 which have nucleotides A and C at the key M4 and M5 positions, respectively, as compared with the repressive regulatory activity observed with V1 URR with G and T residues at these key sites (Figure 3 , bottom panel).
To determine whether these nucleotides at positions M4 and M5 are important for Brn-3a/nicotine effect on the HPV URR, we used mutant constructs with V5, V2 and V1 backbones, containing changes at specific positions (Ndisang et al., 2006b ) for co-transfection assays on SiHa cell lines. The wild-type variants V1 (V11111), V2 (V22222) and V5 (V55555) were used as controls for the transfection assays.
To first determine whether only one of the M4 or M5 nucleotide is required for a positive Brn-3a/nicotine stimulation, we used the low-risk variant 5 backbone mutant constructs, M55515, in which the A at position M4 of V5 was changed to G as in position M4 of V1 (Table 5) , and M55551, in which the C at position M5 of V5 was altered to T as in M5 of V1 (Table 5 ) (Figure 4 , bottom panel) (Ndisang et al., 2006b) .
In these experiments, unlike the wild-type V5 (V55555), the low-risk V5 backbone mutant constructs M55515 and M55551, were stimulated by Brn-3a (Figure 4 , top panels), as observed in our previous study in which we determined the importance of these positions in the response to Brn-3a (Ndisang et al., 2006b) . Most interestingly, upon supplementation with nicotine, the constructs lost their inducibility (Figure 4 , top panels) (Table 5) , thus behaving like variant 1 (Figure 3 , top left panel). This indicates that one or the other of these bases alone (that is A or C) at position M4 or M5 is not sufficient to initiate a positive Brn-3a/ nicotine promoter activity for V5.
To investigate this further, we now used the V5 and V1 backbone mutant contracts, M55511, M55155 and M11555 (Ndisang et al., 2006b) (Figure 4) . Thus, Brn-3a positively stimulated M55511, but upon supplementation with nicotine, the inducibility was abrogated (Figure 4 , middle panel) as in wild-type V1. Interestingly, M55155, registered as a positive promoter stimulation when transfected with Brn-3a, and the inducibility was augmented upon nicotine supplementation (Figure 4 , bottom left panel) (Table 5) , similar to the wild-type V2 and V5. Most interestingly, Brn-3a represses the activity of the intermediate-risk V1 backbone mutant construct M11555, but upon supplementation with nicotine, the promoter was positively induced (Figure 4 , bottom right panel) (Table 5) . Therefore, these data show that the A and C bases at the M4 and M5 positions, as found in the wild types of V2 and V5, respectively, are crucial for the synergistic Brn-3a/ nicotine upregulation of the viral URR and can confer this response to the V1 URR.
To confirm these effects observed with the low-risk V5 mutant constructs, we now used the V2 mutant construct M22522 (Ndisang et al., 2006b) , in which the TC at position M3 of V2 was altered to AT found in V5 (Table 5) . As expected, upon transfection with Brn-3a, this change resulted in the loss of inducibility ( Figure 5 , bottom panel) compared with the wild-type V2 control constructs. Interestingly, inducibility was augmented upon nicotine supplementation ( Figure 5 , bottom panel) (Table 5) , an effect similar to that observed with the mutant constructs M55155 and M11555 (Figure 4 , bottom panels). Hence, basal inducibility by Brn-3a can be dissected away from the combined response to Brn-3a and nicotine. In addition, the independent substitution mutations of the high-risk V2 backbone constructs M22212 and M22221 also behave like the (Table 5) in similar transfection assays. This confirms that the bases at positions 4 and 5 must be A and C, respectively, to produce the synergistic response to Brn-3a/nicotine. Evidently, therefore, only one base (that is G or T) at either the M4 or the M5 position, is sufficient to elicit a negative Brn-3a/nicotine stimulation of the HPV URR as observed with mutant constructs of the high-risk V2 (M22212 and M22221) ( Figure 5, top panel) , the lowrisk V5 (M55515 and M55551) (Figures 4, top panel) , the intermediate-risk V1 (M55511) (Figure 4 , middle panel) and the wild-type V1 (Figure 3 , top left panel) (Table 5 ). In contrast, the synergistic Brn-3a/nicotine stimulation depends on the presence of both the A and C nucleotides being intact at this key putative M4 and (Table 5) .
Discussion
In our previous study, we showed that the URRs of the high-risk HPV variant 2 and the intermediate-risk variant 1 were activated by Brn-3a in transfection assays, whereas the URR of a low-risk variant 5 was Figure 3 The results of co-transfection assay using Brn-3a expression constructs (Brn3a) or control LTR empty expression vector (LTR) and luciferase promoter reporter HPV URR wild-type variant 1 (V1) (top left panel), HPV URR wild-type variant 2 (V2) (top left panel) and HPV URR wild-type variant 5 (V5) (middle panel) in SiHa cervical carcinoma cell line supplemented with 0.1 mM nicotine or cotinine. It must be noted that Brn-3a and nicotine synergistically upregulate the Brn-3a variants 2 and 5 but not variant 1. This activity is correlated with the presence of the nucleotides A and C in position M4 and M5, respectively (bottom panel-also, the diagnostic pattern of the restriction endonuclease SspI and XcmI used for identifying the different variants must be noted) (see text for nomenclature of the constructs).
Brn-3a and nicotine synergistically activate HPV variants D Ndisang et al not (Ndisang et al., 2006b) . We also showed in that study that the change of one or two bases in a low-risk V5 URR to their equivalent in a higher-risk URR can render the URR responsive to Brn-3a and vice versa, indicating that limited sequence differences between different HPV variants can have a dramatic effect on their inducibility by Brn-3a (Ndisang et al., 2006b) . In this study, we showed that, unlike the URR of the intermediate-risk V1, the cellular factor Brn-3a, and the environmental smoking-related substance nicotine, have a combined upregulatory effect on the URRs of the high-risk V2 and the low-risk V5. This correlates with the findings that women smokers with high Brn-3a levels who are infected with either V2 or V5 have augmented E6 levels compared with non-smokers infected with these variants. In turn, these women were frequently diagnosed with higher grades of CIN as compared with non-smokers or ex-smokers with high Brn-3a who were infected with similar variants. Moreover, women who were infected with V2 and expressed Brn-3a in their cervix were shown to be 3.34 times more susceptible to cervical cancer if they smoke, and smokers were 16 times more susceptible to a progressive CIN if they were infected with V5 compared with non-smokers ( Table 4) .
The combined effect of Brn-3a and nicotine on the V2 and V5 variants could be attributed to the two nucleotide differences at the M4 and M5 positions in their URRs, which as we have shown in this report, is crucial for the combined Brn-3a/nicotine response and hence, the effective transcription of the oncogenic E6/E7 product. Indeed, substituting both nucleotide bases in the V2 or V5 URRs to the equivalent in the V1 URR, alters the URR responsive to the Brn-3a and nicotine combined effect and vice versa (Table 5) , indicating again that limited sequence differences between different HPV variants can have a dramatic effect on their inducibility by Brn-3a and nicotine, and hence their transcription of E6. Moreover, the response to Brn-3a and the combined effect of Brn-3a/nicotine can be dissociated from one another, for example, in variant 5 and in several of the mutants.
Taken together, this may explain why even though the mean Brn-3a between women smokers and non-smokers was approximately the same (Tables 1 and 2 ), the mean E6 for the women smokers infected with V2 or V5 was significantly higher than the corresponding E6 for nonsmokers (Table 2 ). This increase in E6 would explain why a high proportion of Brn-3a women smokers who were infected with V2 or V5 were diagnosed with higher CIN grades as compared with Brn-3a non-smokers with similar variants.
On the other hand, nicotine showed an inhibitory effect on the URR of the intermediate-risk V1, and as such, E6 levels were lower in smokers compared with non-smokers with similar Brn-3a levels. Some women smokers who were infected with V1 and expressed Brn3a did register a significant level of E6 levels in their cervix (Table 2) , as expected from the responsiveness of variant 1 due to Brn-3a. This response is dependent on the V1 M3 position (Ndisang et al., 2006b) (Figure 4) , which is identical to that of the highly responsive V2 (Ndisang et al., 2006b) . Therefore, this suggests that the transcription of the oncogenic E6/E7 product in V1 is less dependent on nicotine, but highly dependent on the level of Brn-3a, and hence accounts for the lower E6 observed in the cervix of women smokers infected with V1 as compared with the higher E6 levels observed in women smokers infected with V2, whereas the E6 levels were similar in non-smokers with either V1 or V2 (Table 3) . Brn-3a and nicotine combine effect
Abbreviation: URR, upstream regulatory region. The positive signs signify positive stimulation of the URR by Brn-3a and/or nicotine on transfection assay, whereas the negative signs designate negative stimulation of the URR by Brn-3a and/or nicotine on the same assay. The five sites of the variation are marked in bold as M1-M5 (Ndisang et al., 2006b) , as having the sequence found in variant 5, variant 2 or variant 1. For the nomenclature of the constructs, 'V' designates variant and 'M' mutant. Hence, 'V11111' indicates that the URR contains the base characteristic of variant 1 at each position, whereas '5' indicates that it contains the base characteristic of variant 5 at this position. The altered bases are shown in italics. Thus, 'V11111' denotes wild-type variant 1 (V1), and 'V55555' denotes wild-type variant 5 (V5), whereas M55515 denotes a mutant construct with variant 5 backbone with G (the variant 1 nucleotide base) at position M4. It must be noted that a synergistic effect of Brn3a and nicotine is only obtained when bases M4 and M5 are A and C, respectively, as in variants 2 and 5.
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In turn, these differences may explain why a higher proportion of the low-grade CIN was observed among V1-infected women smokers who presented Brn-3a in their cervix as compared with V2-infected women who presented similar levels of Brn-3a (Tables 2 and 3 ). In contrast, V2-infected women smokers with similar Brn-3a levels in their cervix had a greater proportion of high-grade CIN as compared with the V1-infected women smokers (Tables 2 and 3 ).
In conclusion, we showed in this report that the synergistic effect of Brn-3a and nicotine from smoking upregulates the transcription of the oncogenic E6 protein in the cervix in a variant-specific manner, which may result in a rapid disease progression with significant clinical implications. Hence, to understand the progression of cervical cancer we need to understand the interaction of the cellular transcription factor Brn-3a, the environmental smoking-related substance nicotine and the specific HPV variant present. Such interaction may help to explain why some women who are infected with HPV are susceptible to accelerated CIN progression and cancer and others are not. Importantly, therefore, this information could help in the developing world in particular, to increase awareness of the necessity of avoiding active and passive smoking, which could have enormous implications on the costeffectiveness for their cervical and public health programmes. Figure 4 The results of luciferase assay with Brn-3a expression vector or the empty expression vector and the reporter HPV URR variant 5 and variant 1 mutant contructs in SiHa cervical carcinoma cell line supplemented with nicotine. The effect of altering the bases in varaint 5 (V5) (Ndisang et al., 2006b ) at position 4 M55515 by substituting with that of the equivalent position of variant V1 (V1), or at position 5 M55551 by the same position found in V1 (top panel) and at position 3 M55155 (bottom left panel), by the equivalent position in V1 must be noted. In addition, the effect of substituting both the M4 and M5 bases of V5 with that of V1 to generate M55511 (middle panel), and the V1 backbone mutant construct M11555 generated from fragments from the V1 backbone mutant 11511 and that of the V5 backbone mutant 55155 must be noted. The controls are the wild-type V1, V2 and V5 (Figure 3 ) (see text for the nomenclature of the constructs).
Materials and methods

Patients and clinical samples
This study comprised two geographically distinct groups of patients infected with HPV who were smokers, non-smokers or ex-smokers. Group one comprised patients in London, England in the United Kingdom, a developed country, and group two composed of patients in Recife, Brazil, a developing country. The study group in London consisted of 270 women who were referred to either the colposcopy or gynaecological clinics at The Whittington District and Teaching Hospital, London. The mean age for the London cohort was 34.7 years, the median 31 years and the range 17-89 years. Smoking status was based on smoking at least 10 cigarettes per day. There were 120 smokers, 141 non-smokers and 9 ex-smokers. Among this group, 90 individuals were infected with HPV variant 1, variant 2 or variant 5; of these, 34 were smokers, 47 were non-smokers and 9 were ex-smokers. The study group in Recife, Brazil, consisted of 86 women histologically diagnosed with HPV-associated cervical abnormalities and attending one of the following gynaecological units: (1) Instituto Materno Infantil De Pernambuco (IMIP) Recife, Pernambuco Brazil, (2) The Gynaecological Oncology Research Unit Bar de Lucena Hospital, Recife and (3) The Cancer Hospital Recife. The mean age for this group was 40.8 years; median was 37.5 years and the range 21-93 years. Among the 86 women from Recife, Brazil, 68 were infected with HPV variant 1, variant 2 or variant 5; of these, 35 were smokers, 33 were non-smokers and there were no ex-smokers, although 18 women who smoked both pipes and cigarettes were evaluated for a separate study.
Thus, a total of 158 women in both groups (that is, 90 from London, UK, and 68 from Recife, Brazil) of this study were infected with variant 1, variant 2 or variant 5, of which 61 had high-grade CIN, 52 low-grade CIN, 40 borderline and 5 cervical cancer. In both groups, ethical permission was obtained from the respective hospital's ethics committee after review of the study protocol. All the women in both groups provided informed consent to obtain and use their cervical material for this study.
Measurement of Brn-3a and HPV E6 levels in cervical material
The Brn-3a and HPV E6 mRNA levels in cervical material was determined using our previously described reverse-transcriptase PCR assay (Sindos et al., 2003a, b; Ndisang et al., 2006a, b) . Routinely, B0.1 mg of Dnase-treated RNA extracted from cervical material was used as a template for cDNA synthesis. Equal amounts of the resultant cDNA were then used for reverse-transcriptase PCR as described in the studies by Sindos et al. (2003a, b) and Ndisang et al. (2006a, b) .
RFLPof PCR products
The RFLP assay was adapted from the study by Bible et al. (2000) , and used as in our previous study (Ndisang et al., 2006b) , to type the different HPV variants in clinical samples. Briefly, 1 ml of DNA derived from the cervical smear treated with 250 mg/ml RNase was amplified using a hot start of 95 1C and annealing temperature of 55 1C for 40 cycles using HPV-16 E5 primers (Bible et al., 2000) . The resultant amplicons were purified by ethanol precipitation and resuspended to appropriate amounts in suitable distilled water, and then aliquots of 5 ml were respectively digested overnight at 37 1C using one of Brn-3a and nicotine synergistically activate HPV variants D Ndisang et al the following restriction endonuclease (NspI, XcmI and SspI; New England Biolabs, Hertfordshire, UK) as per the manufacture's instruction. The digested products were then analysed on 2% ethidium bromide-stained agarose gel.
Generation of E6 URR variant constructs
The generation of E6 URR variants and luciferase constructs and the sequence analysis of the URR of different HPV-16 variants are described in the study by Ndisang et al. (2006b) . Briefly, E6 promoter fragments were amplified from cervical smears infected with HPV-16 variant 1, variant 2 and variant 5 DNA, using primers 'E6-upstream-Xho' and 'E6-downstreamNcoI' (Ndisang et al., 2006b) . The annealing temperature used was 65 1C. The amplified products were cloned into the pGL3-Basic Luciferase reporter vector (Promega, Southampton, UK) using restriction sites XhoI and NcoI (Ndisang et al., 2006b) . The resulting clones were sequenced in both directions (MWG-Biotech, Ebersberg, Germany) to confirm insertion in frame, and to identify sequence differences between variants. Constructs were termed 'variant 1 (V1)', 'variant 2 (V2)' and 'variant 5 (V5)'.
Transfections and reporter gene assay
The transfection assay used in this study was described in the studies by Lee et al. (2005) and Ndisang et al. (2006b) . Briefly, SiHa cells (ATCC, Virginia, VA, USA) were routinely grown in minimum essential medium (Eagle's), supplemented with 10% fetal calf serum, 0.1 mM non-essential amino acids and 1.0 mM sodium pyruvate. SiHa cells were transfected by the calcium phosphate method as described previously (Ndisang et al., 1999) . In brief, 1 mg of the HPV variant URR recombinant pGL3 reporter plasmid was co-transfected with 1 mg of the expression vector pLTRpoly (ATCC) containing the full-length cDNA of Brn-3a transcription factor under the Moloney murine leukaemia virus promoter (Ndisang et al., 1999 (Ndisang et al., , 2001 ) and 0.1 mg of TK-Renilla plasmid (Promega) as an internal control onto 0.7 Â 10 5 SiHa cells and supplemented with (0. m1 M) nicotine (Sigma-Aldrich, Dorset, UK) or cotinine (Sigma-Aldrich), which is consistent with several studies using low concentrations of nicotine typically in the range of 100 nM-10 mM to induce putative effects (Harkness and Millar, 2002; Lane et al., 2005; Dasgupta et al., 2006a) , given that 1 mM of nicotine is equivalent to the amount present in the blood stream of those who smoke one pack of cigarettes per day (Hellberg et al., 1988; Dasgupta et al., 2006b ). In our study, 100 nM, that is, 0.1 mM of nicotine was the ideal concentration for the maximum survival of SiHa cells after 48 h. Thereafter, SiHa cells were harvested and washed with 1 Â phosphate-buffered saline.
Luciferase assay of reporter gene activity Routinely, as described in the study by Ndisang et al. (2006b) , transfected cells were lysed in 1 Â passive lysis buffer (Promega) and assayed for both firefly and Renilla luciferase activities according to the manufacturer's protocol, with results measured and quantified on a TD-20e Luminometer, Promega Turner BioSystems, Southampton, UK. The relative luciferase units, which is the ratio of the firefly's activity to that of the Renilla, was then obtained. Each transfection was performed in triplicate and thus, mean and s.d. were determined.
Statistical analysis
The differences of the mean between variables and the coefficient of regression were analysed using the bundle Microsoft Excel (Microsoft, Berkshire, UK) Student's t-test and ordinal regression analysis software. Odd ratios, relative risk and confidence intervals were estimated by multiple logistic regressions to determine the association between the variants and CIN by using the UCL Statistics and Research Methodology software (University College London, London, UK). At all instances, P-values of o0.05 (Po0.05) with 95% confidence interval was used as the cutoff for statistical significance.
Abbreviations URR, upstream regulatory region; CIN, cervical intraepithelial neoplasia.
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